SACK1C

Summary

SACK1C (scaffolding CK1 anchoring protein C, HGNC:16121) is a protein-coding gene on chromosome 20q11.22, encoding Protein FAM83C (Q9BQN1). May play a role in MAPK signaling.

This gene encodes a member of the family with sequence similarity 83 protein family. The encoded protein may be involved in regulating MAPK signaling in cancer cells.

Source: NCBI Gene 128876 — RefSeq curated summary.

At a glance

• GWAS associations: 19
• Clinical variants (ClinVar): 155 total
• MANE Select transcript: NM_178468

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16121
Approved symbol	SACK1C
Name	scaffolding CK1 anchoring protein C
Location	20q11.22
Locus type	gene with protein product
Status	Approved
Aliases	dJ614O4.7
Ensembl gene	ENSG00000125998
Ensembl biotype	protein_coding
Entrez	128876

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000374408

RefSeq mRNA: 1 — MANE Select: NM_178468 NM_178468

CCDS: CCDS13251

Canonical transcript exons

ENST00000374408 — 4 exons

Exon	Start	End
ENSE00000860200	35288461	35288585
ENSE00000860201	35288791	35288958
ENSE00001759967	35291792	35292425
ENSE00001898415	35285731	35287972

Expression profiles

Bgee: expression breadth broad, 74 present calls, max score 98.65.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2153 / max 54.0349, expressed in 39 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187040	0.1645	35
187039	0.0508	24

Top tissues by expression

211 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	98.65	gold quality
gingiva	UBERON:0001828	97.94	gold quality
esophagus squamous epithelium	UBERON:0006920	97.09	gold quality
penis	UBERON:0000989	96.27	gold quality
sperm	CL:0000019	95.75	gold quality
upper leg skin	UBERON:0004262	94.85	gold quality
mammalian vulva	UBERON:0000997	94.61	gold quality
skin of hip	UBERON:0001554	94.24	gold quality
nipple	UBERON:0002030	93.08	gold quality
pharyngeal mucosa	UBERON:0000355	91.95	gold quality
oral cavity	UBERON:0000167	89.88	gold quality
zone of skin	UBERON:0000014	89.71	gold quality
skin of leg	UBERON:0001511	89.23	gold quality
skin of abdomen	UBERON:0001416	88.99	gold quality
esophagus mucosa	UBERON:0002469	88.51	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.66	gold quality
lower esophagus mucosa	UBERON:0035834	86.09	gold quality
tendon of biceps brachii	UBERON:0008188	85.38	gold quality
buccal mucosa cell	CL:0002336	82.35	silver quality
body of tongue	UBERON:0011876	81.85	gold quality
tongue	UBERON:0001723	77.45	gold quality
parotid gland	UBERON:0001831	75.14	gold quality
vagina	UBERON:0000996	74.91	gold quality
superior surface of tongue	UBERON:0007371	72.66	gold quality
palpebral conjunctiva	UBERON:0001812	71.65	gold quality
epithelium of nasopharynx	UBERON:0001951	71.13	gold quality
amniotic fluid	UBERON:0000173	70.21	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	69.89	gold quality
medial globus pallidus	UBERON:0002477	69.69	silver quality
nasal cavity epithelium	UBERON:0005384	68.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting SACK1C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-1272	99.34	68.79	878
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-4801	98.96	69.42	2096
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-4731-3P	98.56	68.60	1860
HSA-MIR-6852-3P	98.54	67.60	1468
HSA-MIR-96-3P	97.47	68.03	839
HSA-MIR-512-5P	97.47	66.48	591
HSA-MIR-1306-5P	97.11	64.04	755
HSA-MIR-346	97.01	66.97	662

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam83c	ENSDARG00000075296
mus_musculus	Fam83c	ENSMUSG00000074647
rattus_norvegicus	Fam83c	ENSRNOG00000046772

Paralogs (7): FAM83D (ENSG00000101447), FAM83E (ENSG00000105523), FAM83F (ENSG00000133477), FAM83A (ENSG00000147689), FAM83B (ENSG00000168143), FAM83H (ENSG00000180921), FAM83G (ENSG00000188522)

Protein

Protein identifiers

Protein FAM83C — Q9BQN1 (reviewed: Q9BQN1)

All UniProt accessions (1): Q9BQN1

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in MAPK signaling.

Subunit / interactions. May interact with RAF1.

Subcellular location. Cytoplasm.

Post-translational modifications. Phosphorylated in vitro by CSNK1A1.

Domain organisation. All members of the FAM83 family of proteins share a conserved N-terminal DUF1669 (domain of unknown function 1669) domain of about 300 amino acids. This domain mediates the interaction with casein kinase 1 (CK1) isoforms. Therefore, it has been proposed to rename DUF1669 the polypeptide anchor of CK1 domain.

Similarity. Belongs to the FAM83 family.

RefSeq proteins (1): NP_848563* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012461	SACK1	Domain
IPR050944	FAM83	Family

Pfam: PF07894

UniProt features (20 total): region of interest 8, sequence variant 4, compositionally biased region 3, mutagenesis site 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQN1-F1	56.81	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (2):

Position	Phenotype
259	diffuse cytoplasmic localization, loss of localization along fibrous structures, possibly due to loss of interaction wit
293	diffuse cytoplasmic localization, loss of localization along fibrous structures, possibly due to loss of interaction wit

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 21 (showing top): NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON, chr20q11, GOMF_KINASE_BINDING, RICKMAN_HEAD_AND_NECK_CANCER_E, MARTENS_TRETINOIN_RESPONSE_UP, ZNF184_TARGET_GENES, MIR6867_5P, MIR1272, MIR3682_3P, GSE15659_CD45RA_NEG_CD4_TCELL_VS_RESTING_TREG_UP, GSE15659_CD45RA_NEG_CD4_TCELL_VS_NONSUPPRESSIVE_TCELL_UP, GSE15659_NONSUPPRESSIVE_TCELL_VS_ACTIVATED_TREG_UP, GAO_ESOPHAGUS_25W_C4_FGFR1HIGH_EPITHELIAL_CELLS, DESCARTES_MAIN_FETAL_SQUAMOUS_EPITHELIAL_CELLS, DESCARTES_FETAL_STOMACH_SQUAMOUS_EPITHELIAL_CELLS

GO Biological Process (1): signal transduction (GO:0007165)

GO Molecular Function (2): protein kinase binding (GO:0019901), protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
kinase binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

798 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SACK1C	RBM33	Q96EV2	507
SACK1C	PGBD5	Q8N414	506
SACK1C	GGT7	Q9UJ14	496
SACK1C	KIF22	Q14807	433
SACK1C	TTBK2	Q6IQ55	432
SACK1C	ZFP91	Q96JP5	422
SACK1C	DYNLL1	P63167	406
SACK1C	SUSD1	Q6UWL2	402
SACK1C	SACK1H	Q6ZRV2	396
SACK1C	EVA1C	P58658	385
SACK1C	TPRG1	Q6ZUI0	371
SACK1C	RTP5	Q14D33	370
SACK1C	CCDC157	Q569K6	357
SACK1C	FOXRED2	Q8IWF2	356
SACK1C	TBC1D31	Q96DN5	349

IntAct

10 interactions, top by confidence:

A	B	Type	Score
FAM83C	CSNK1A1	psi-mi:“MI:0914”(association)	0.610
FAM83C	CSNK1A1	psi-mi:“MI:0915”(physical association)	0.610
CSNK1A1	FAM83C	psi-mi:“MI:0403”(colocalization)	0.610
CSNK1A1	FAM83C	psi-mi:“MI:0217”(phosphorylation reaction)	0.610
FAM83C		psi-mi:“MI:0915”(physical association)	0.400
APOA1	CNMD	psi-mi:“MI:0914”(association)	0.350
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350

BioGRID (3): FAM83C (Proximity Label-MS), FAM83C (Affinity Capture-MS), FAM83C (Affinity Capture-MS)

ESM2 similar proteins: A2ARK0, A3KN19, A6ND36, E9Q0S6, E9Q2Z1, G5E5X0, O70405, O75385, O94983, O95402, P42335, Q04205, Q08EC4, Q32PJ7, Q3UJB9, Q3ZAV8, Q5D1E7, Q5D1E8, Q5PQS0, Q5SSZ5, Q5SWY7, Q5XIS1, Q5XK72, Q63HR2, Q68CZ2, Q6P2E9, Q6PDH0, Q7TSI1, Q80Y50, Q86UU1, Q8BG26, Q8C2B3, Q8CGB6, Q8IUC6, Q8K1S6, Q8K2P2, Q8K330, Q8TE77, Q8TF72, Q8WUI4

Diamond homologs: A1L1G9, A2ARK0, A3KN19, A4QP72, A6ND36, A9JRM0, Q0VBM2, Q148V8, Q1LVV0, Q2M2I3, Q3UKU4, Q5SWY7, Q5T0W9, Q5XGY0, Q5XK72, Q66JF7, Q6PF42, Q6ZRV2, Q80XS7, Q86UY5, Q8K2P2, Q8NEG4, Q9BQN1, Q9D7I8, Q9H4H8, Q1RK58, Q4UJZ1, Q68VT0, Q9ZCD8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
FAM83C	“up-regulates quantity”	CSNK1A1	binding
FAM83C	“up-regulates quantity”	CSNK1A1L	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

155 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	136
Likely benign	15
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

653 predictions. Top by Δscore:

Variant	Effect	Δscore
20:35287968:TGAAG:T	acceptor_gain	1.0000
20:35287971:AG:A	acceptor_gain	1.0000
20:35287973:C:CC	acceptor_gain	1.0000
20:35288457:TCAC:T	donor_loss	1.0000
20:35288460:CCT:C	donor_loss	1.0000
20:35288583:GTT:G	acceptor_gain	1.0000
20:35288584:TT:T	acceptor_gain	1.0000
20:35288785:A:AC	donor_gain	1.0000
20:35288786:C:CA	donor_gain	1.0000
20:35288786:CTGA:C	donor_gain	1.0000
20:35288789:A:AC	donor_gain	1.0000
20:35288790:C:CC	donor_gain	1.0000
20:35288790:CCGG:C	donor_gain	1.0000
20:35288790:CCGGC:C	donor_loss	1.0000
20:35288802:C:CA	donor_gain	1.0000
20:35288803:C:A	donor_gain	1.0000
20:35288955:CCAC:C	acceptor_gain	1.0000
20:35288956:CAC:C	acceptor_gain	1.0000
20:35288956:CACC:C	acceptor_gain	1.0000
20:35288957:AC:A	acceptor_gain	1.0000
20:35288957:ACC:A	acceptor_loss	1.0000
20:35288958:CC:C	acceptor_gain	1.0000
20:35288958:CCTG:C	acceptor_loss	1.0000
20:35288959:C:CC	acceptor_gain	1.0000
20:35288959:CT:C	acceptor_loss	1.0000
20:35288960:T:C	acceptor_loss	1.0000
20:35288963:G:C	acceptor_gain	1.0000
20:35288963:G:GC	acceptor_gain	1.0000
20:35291788:TTACC:T	donor_loss	1.0000
20:35291789:TA:T	donor_loss	1.0000

AlphaMissense

4796 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:35287889:A:G	F297S	0.997
20:35287919:C:A	G287V	0.996
20:35287965:A:G	W272R	0.996
20:35287965:A:T	W272R	0.996
20:35291911:A:G	W132R	0.996
20:35291911:A:T	W132R	0.996
20:35287888:G:C	F297L	0.995
20:35287888:G:T	F297L	0.995
20:35287890:A:G	F297L	0.995
20:35288951:G:T	A174D	0.995
20:35288906:A:G	L189P	0.994
20:35291909:C:A	W132C	0.994
20:35291909:C:G	W132C	0.994
20:35287920:C:G	G287R	0.993
20:35288502:G:C	F255L	0.993
20:35288502:G:T	F255L	0.993
20:35288504:A:G	F255L	0.993
20:35291828:C:A	K159N	0.993
20:35291828:C:G	K159N	0.993
20:35288933:A:G	F180S	0.992
20:35287900:A:C	F293L	0.991
20:35287900:A:T	F293L	0.991
20:35287902:A:G	F293L	0.991
20:35287963:C:A	W272C	0.991
20:35287963:C:G	W272C	0.991
20:35292127:A:C	Y60D	0.991
20:35287925:A:G	L285P	0.990
20:35288466:A:C	S267R	0.990
20:35288466:A:T	S267R	0.990
20:35288468:T:G	S267R	0.990

dbSNP variants (sampled 300 via entrez): RS1000003474 (20:35292898 G>A), RS1000150706 (20:35286300 C>T), RS1000354933 (20:35293074 A>G), RS1000752082 (20:35288775 C>G,T), RS1001004096 (20:35289971 C>T), RS1001186821 (20:35292587 C>T), RS1001414016 (20:35294052 G>A), RS1002065827 (20:35288184 C>T), RS1002749965 (20:35285889 C>G,T), RS1002858734 (20:35291551 T>C), RS1003107334 (20:35286267 C>T), RS1003642414 (20:35287383 G>A), RS1003765128 (20:35286894 T>A,C), RS1003920525 (20:35285498 G>T), RS1003921150 (20:35288183 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST005956_31	Waist-to-hip ratio adjusted for BMI	8.000000e-08
GCST005958_16	Waist-to-hip ratio adjusted for BMI (age >50)	6.000000e-06
GCST005962_40	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	3.000000e-08
GCST007294_22	Body fat distribution (trunk fat ratio)	4.000000e-48
GCST007294_41	Body fat distribution (trunk fat ratio)	6.000000e-38
GCST007295_10	Body fat distribution (leg fat ratio)	3.000000e-09
GCST007295_170	Body fat distribution (leg fat ratio)	3.000000e-43
GCST007295_4	Body fat distribution (leg fat ratio)	1.000000e-40
GCST008163_320	Height	2.000000e-11
GCST010142_10	Fish- and plant-related diet	8.000000e-12
GCST010703_112	Brain morphology (MOSTest)	4.000000e-19
GCST012227_1094	Hip circumference adjusted for BMI	5.000000e-19
GCST012227_1099	Hip circumference adjusted for BMI	3.000000e-16
GCST012228_445	Waist-hip index	6.000000e-10
GCST012230_186	Waist-to-hip ratio adjusted for BMI	4.000000e-11
GCST90002385_535	High light scatter reticulocyte count	7.000000e-09
GCST90002405_448	Reticulocyte count	1.000000e-10
GCST90002406_552	Reticulocyte fraction of red cells	2.000000e-10
GCST90020028_1523	Hip circumference adjusted for BMI	1.000000e-12

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004341	body fat distribution
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0007986	reticulocyte count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
sodium arsenate	decreases expression, increases abundance	1
(+)-JQ1 compound	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Allergens	increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Diethylhexyl Phthalate	decreases expression	1
Sodium Dodecyl Sulfate	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1
Permethrin	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer